| Literature DB >> 32318926 |
Li Huang1, Chanjuan Shen2, Yong Zhong3, Joshua D Ooi4, Ya-Ou Zhou5, Jin-Biao Chen6, Ting Wu7, Ting Meng7, Zhou Xiao7, Wei Lin8, Xiang Ao7, Rong Tang7, Xiangcheng Xiao7, Qiaoling Zhou7, Ping Xiao7.
Abstract
Neutrophil-to-lymphocyte ratio (NLR) has been recently reported to be a promising inflammatory marker to assess systemic inflammation in many disorders. However, there are only a few studies looking at NLR in patients with myeloperoxidase (MPO)-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This study was thus undertaken to explore the relationship between NLR at diagnosis with inflammatory response and disease activity among MPO-AAV patients in a single Chinese center. Furthermore, we evaluated whether NLR could predict the renal prognosis and patient outcome. 188 patients with MPO-AAV were included in this study. Baseline NLR was positively correlated with CRP (r = 0.404, P < 0.001) and negatively with serum levels of C3 (r = - 0.163, P = 0.035), but it had no obvious correlation with Birmingham Vasculitis Activity Score (BVAS). Patients with MPO-AAV having NLR ≥ 9.53 exhibited higher risk for all-cause mortality than those having NLR < 9.53 (P < 0.0001). However, no significant difference was found in the kidney survival between patients having NLR ≥ 9.53 and those NLR < 9.53 at diagnosis. In multivariate analysis, NLR was positively associated with all-cause mortality (P = 0.037, HR = 1.98, 95% CI 1.04-3.78). There was no association between NLR with ESRD observed using univariate analysis or multivariate analysis. This large retrospective study of MPO-AAV patients in a single Chinese center demonstrates that NLR positively correlates with CRP and negatively correlates with serum levels of C3 in Chinese patients with MPO-AAV. Importantly, higher NLR predicts increased mortality and is, therefore, a useful independent prognostic in MPO-AAV.Entities:
Keywords: Anti-neutrophil cytoplasmic antibody-associated vasculitis; Mortality; Myeloperoxidase; Neutrophil-to-lymphocyte ratio
Mesh:
Substances:
Year: 2020 PMID: 32318926 DOI: 10.1007/s10238-020-00629-0
Source DB: PubMed Journal: Clin Exp Med ISSN: 1591-8890 Impact factor: 3.984